Some of the biotechs and pharma companies my have been overpriced. This sector pricing is based on future earnings. How much do you think HALO would be worth if there is news that the phase 3 trials produced excellent results? Same with the other stocks as well. You buy at these levels looking for huge earnings later. Clinton is part of the problem with our current government - rob from the rich and give to the poor. My health insurance that I loved two years ago was cancelled for not meeting the new AHC standards. My new plan has a 6 thous deductible and the premiums doubled. Biotechs take huge risks to bring a new product to the market. If they are restricted in recovering their expenses who will want to look for cures for incurable diseases?
I thought this all started with the pharma sector when Hillary Clinton said she would rein in the profits on the pharma companies.
There is considerable activity in the August options currently expire on August 21st Until then expect these volativity
Brocade does not report for another month so there should be no preliminary results out for some time yet. The downgrade was more than likely a sector downgrade and not based on results from Brocade.
Yep. At the time I wrote that the volume was only 95,00 shares. On the plus side the stock has held at high 24's with increased volume.
I also bought on Thursday. I believe the value of the parts is greater than the value of the whole and it seems like Columbia is fairly priced. I believe the value of Ni will be determined in part by the future dividend.
I am expecting some who bought NI to capture the spin off will sell in the morning after they receive their CPGX.
I don't think this is personal. The "financial advisers" representing MCGC in the sale stand to lose their fees if the PFLT deal is not consummated. HC2 will not get anywhere with this unless they sue the board of MCGC.
Good luck with that. A short sale when the stock had it's last big run up was smart. Shorting now at these levels is not smart. There is support at $2.60 which leaves little downside.
Are you sure about that? The $2.50 level is support that has been tested several times the last few days and held. This looks more like a bounce off the support that will run all the way to the mid threes short term.
All of the biotech companies that "were big winners" in the recent presentations have spiked and pulled back to levels in some cases that are below the levels prior to the run up. The chart for VBLT looks to be no different so I am expecting $4-5 after the selling is over. Then it will go to sleep for a while and at some point we will repeat the cycle.
I did read the SEC filings. I stand by my opinion that Morgan Stanley is pushing the PFLT deal as they would stand to make a tidy commission with that transaction. HCHC does have a little bit of a troublesome history but that was then and this is now and the offer is considerably better that the PFLT offer. And I still think there will be a class action lawsuit if the HCHC offer is not presented to the shareholders.
There is no question that the price has been driven down after what would normally be considered good news from the ongoing clinical trials. Today's trading action is interesting in that the volume is far above average and the price has found support at the $2.80 level. It may never reach $2.50.
Latest HCHC offer rejected. There will be a class action law suit over this as there is a more than 10% differential in the offering prices. It would seem to appear that the board is being led by the lead brokerage firms representing them.
$8 is not going to happen. In consideration of forward looking guidance (which is up from a year ago) the forward PE will be around 12-15 which is very reasonable if not cheap. Good luck to you if you are short.
The private placement investor has to be laughing all the way to the bank. A quick 15 million dollar gain. Of course, I am assuming that they are the sellers today. If they are not the sellers then the new investors are at risk for any new investment above $1.73 per share until the 15 million shares are liquidated.